Preventing esophageal varices in liver cancer patients treated with specific medications

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective cohort study aims to evaluate the progression of esophageal varices in patients with hepatocellular carcinoma (HCC) who are being treated with atezolizumab and bevacizumab. The study will assess the efficacy of primary prophylaxis for small esophageal varices without risky signs and will explore the impact of shortening endoscopic follow-up intervals to mitigate the risk of variceal hemorrhage. Participants will undergo regular endoscopic examinations at 3, 6, 9, and 12 months to monitor variceal progression and may receive esophageal band ligation before starting therapy to prevent further complications.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with confirmed advanced HCC (Diagnosed by two imaging modalities or liver biopsy) eligible for atezolizumab-bevacizumab therapy.
* Patients with preserved liver function (compensated Child-Pugh A if there is underlying cirrhosis).
* Patients with performance status ≤2 at staging work-up.
* Patients with no or grade 1 non-risky esophageal varices on pretreatment endoscopic examination.

Exclusion Criteria:

* Child-Pugh class C patients.
* Patients with performance status \>2 at staging work-up.
* Vascular disorders and arterial hypertension.
* Severe autoimmune disorders.
* Patients who lost follow-up.
* Pregnant or breastfeeding women.
* Unwilling to participate in our study.

Where it's running

• Tanta University Hospitals
  Tanta, Gharbyea, Egypt Recruiting

Study contacts

• Principal investigator: Rania M Elkafoury, MD — Tropical medicine and infectious diseases Department, Faculty of Medicine, Tanta University
• Study coordinator: Rania M Elkafoury, MD
• Email: rania.elkafoury@med.tanta.edu.eg
• Phone: +201004672358

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood biomarkers to predict response to atezolizumab plus bevacizumab in hepatocellular carcinoma

  This study tests whether blood-based biomarkers can predict which patients with advanced liver cancer will respond to first-line atezolizumab plus bevacizumab.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07734857

• TIPS benefits for people with hepatocellular carcinoma taking Tecentriq (atezolizumab) plus Avastin (bevacizumab) as first-line therapy.

  This study will try to see if placing a TIPS device helps people with advanced or unresectable hepatocellular carcinoma who are starting first-line treatment with Tecentriq plus Avastin.

  Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Düsseldorf, North Rhine-Westphalia · NCT07365930

• FOLFOX chemotherapy with atezolizumab and bevacizumab after progression on atezolizumab plus bevacizumab for advanced liver cancer

  This trial will test whether giving FOLFOX chemotherapy together with continued atezolizumab and bevacizumab helps people with advanced hepatocellular carcinoma whose cancer progressed on prior atezolizumab plus bevacizumab.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07192185

• Real-life experience with immunotherapy for liver cancer treatment

  This study is testing new combinations of immunotherapy treatments for liver cancer to see how well they work and how safe they are for patients.

  Recruiting at 16 sites IRCCS Azienda Ospedaliero-Universitaria di Bologna · Torrette, AN and 23 other locations · NCT06806579

• Combining radiotherapy and immunotherapy for advanced liver cancer before transplant

  This study is testing if combining radiation therapy with immunotherapy can help people with advanced liver cancer get better and qualify for a liver transplant.

  Recruiting Phase 1/2 University Health Network, Toronto · London, Ontario and 1 other locations · NCT06725121

• Evaluating RZ-001 with Valganciclovir and Atezolizumab/Bevacizumab for Liver Cancer

  This study is testing a new combination treatment for advanced liver cancer to see if it is safe and effective for patients with a specific type of the disease.

  Recruiting at 9 sites Phase 1/2 Rznomics, Inc. · Busan and 8 other locations · NCT06695026

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.